Danaher, a diversified conglomerate, completed the acquisition of CEVEC Pharmaceuticals, a provider of high-performance cell line development and viral vector manufacturing technologies. Financial terms were not disclosed. "We are excited to become part of Cytiva. Combined with Cytiva's global presence and leading brands, this enables the whole gene therapy industry to embark on new and powerful solutions for scalable vector manufacturing and start a new era for therapies made available to patients in need," Nicole Faust, CEVEC Pharmaceuticals CEO.